Search

everythinglearnresearchcommunity

for

Search:↓

Capivasertib improves survival in certain breast cancer cases but requires careful management of side effects.

A woman's vitiligo improved with tofacitinib treatment, and her skin color remained even after stopping the medication, but there are concerns about cancer risk.

Ripretinib is effective and safe for treating advanced GIST in Chinese patients, particularly for non-gastric GISTs.

The combination of encorafenib and binimetinib caused few skin issues.

Pemigatinib may be effective for treating ZMYM2::FGFR1 fusion-positive leukemia.

A man with lung cancer had skin and eye side effects from erlotinib but continued treatment with symptom improvement.

Topical aprepitant reduces skin rash and hair loss caused by cancer treatment.

Imatinib mesylate can cause skin lightening, especially in Chinese patients, due to its effect on pigment production.

Imatinib can repigment grey hair, while SU11428 can cause temporary hair depigmentation.

Tofacitinib improved ulcerative colitis, skin ulcers, and hair loss in a patient who didn't respond well to other treatments.

Tofacitinib might be used to treat hair loss.

Afatinib can cause eyelash and eyebrow issues, leading to eye irritation and pain.

The drug showed promise in treating renal cell carcinoma with manageable side effects.

Dabrafenib was effective and well tolerated in treating thyroid cancer with a specific mutation.

Tofacitinib may effectively treat skin symptoms in difficult cases of dermatomyositis.

Erlotinib causes skin inflammation through IL-1, which can be reduced by anakinra.

JAK inhibitors help treat some diseases but may increase risks of blood clots and cancer in certain patients.

Oral tofacitinib shows promise in treating atopic dermatitis and alopecia areata, but only slight improvement in vitiligo.

Tofacitinib helped regrow hair in patients with alopecia, with few side effects.

Janus Kinase inhibitors are effective and have an acceptable safety profile for treating moderate to severe Ulcerative Colitis.

Selumetinib causes fewer and less severe skin issues in children than binimetinib.

Axitinib treatment turned a man's grey hair back to black.

Selumetinib effectively reduces tumor size in many children with neurofibromatosis type 1, but can cause skin and hair issues.

Promising cancer treatments were found, but the manufacturer closed.

Nilotinib can cause keratosis pilaris, a skin condition.

Ivarmacitinib significantly improved hair regrowth in severe alopecia areata after tofacitinib was less effective.

Tofacitinib is effective and safe for treating severe hair loss in Korean patients.